High Tide Posts Record Revenue and EBITDA on Strong Retail and Medical Cannabis Growth

Event summary

  • High Tide reported record revenue of $179.3 million for Q2 2026, up 30% year-over-year.
  • Adjusted EBITDA reached $13.9 million, a 73% increase compared to the same period last year.
  • Remexian Pharma GmbH, High Tide's German medical cannabis subsidiary, generated record revenue of $31.6 million with gross margins increasing to 27%.
  • High Tide secured $40 million in credit facilities from Bank of Montreal to fuel further non-dilutive growth.
  • Canadian Cabana Club membership exceeded 2.65 million, up 39% compared to the previous year.

The big picture

High Tide's strong Q2 2026 results highlight its strategic focus on integrating its medical cannabis distribution arm, Remexian, and expanding its retail footprint in Canada. The company's ability to secure non-dilutive credit facilities underscores its financial health and growth potential. As the cannabis industry continues to evolve, High Tide's diversified approach positions it well to capitalize on both domestic and international opportunities, particularly in the medical cannabis sector.

What we're watching

Retail Dominance
Whether High Tide can sustain its 12% market share in Canadian cannabis retail amid increasing competition.
European Expansion
The pace at which High Tide can expand its medical cannabis distribution beyond Germany into other European markets.
Regulatory Shifts
How potential U.S. federal cannabis rescheduling will impact High Tide's strategic positioning and market opportunities.

Related topics

EBITDA